1. Belgium Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Galapagos N.V.

Galapagos N.V.

GLPG.BR
Galapagos N.V.BE flagEuronext Brussels
15.99
EUR
- -
- -
Galapagos N.V.
GLPG.BR
(Euronext Brussels)

Recent

price

15.99

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
5.04
3.63
5.13
2.66
2.3
1.11
2.83
2.57
5.35
14.49
7.35
3.58
3.67
3.64
4.17
16.88
15.84
Revenue per Share
0.18
-1.25
-0.22
-0.28
1.1
-3.32
1.18
-2.34
-0.56
2.6
-4.69
-1.58
-3.32
3.21
1.12
4.87
7.42
Basic EPS, GAAP
-0.94
-0.68
2.16
-0.21
-2.6
-3.4
5.13
-3.12
-3
54.9
-7.97
-8.58
-8.19
-6.45
-6.08
-4.12
-4.71
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
3.17
1.75
1.68
1.89
3.1
0.23
2.44
0.44
-1.18
3.09
-0.67
-1.15
-3.09
1
2.41
7.66
7.93
Book Value per Share
3.81
2.61
2.69
4.17
6.78
10.18
16.58
20.4
23.23
49.48
40
39.44
35.18
39.43
40.25
49.09
49.38
Tangible Book Value per Share
24
26
27
29
30
36
46
49
52
58
65
66
66
66
66
66
66
Basic Weighted Avg Shares
122
96
136
77
69
40
130
127
279
835
478
234
241
240
276
1,112
1,044
Sales/Revenue/Turnover
1.2
-36.59
-1.54
-21.69
-51.83
-226.09
-8.87
-70.66
-16.89
44.17
-37.37
-73.2
-54.32
-36.82
-68.33
45.08
57.14
Operating Margin (%)
12
12
9
8
5
3
4
4
5
12
19
35
66
44
45
56
- -
Depreciation Expense
4
-33
-6
-8
33
-118
54
-116
-29
150
-305
-103
-218
212
74
321
489
Net Income, GAAP
- -
- -
- -
- -
- -
- -
0.43
- -
- -
- -
- -
- -
- -
170.9
- -
- -
0.59
Effective Tax Rate (%)
3.57
-34.52
-4.2
-10.54
47.88
-299.3
41.7
-91.04
-10.5
17.95
-63.89
-44.04
-90.36
88.31
26.88
28.85
46.83
Profit Margin (%)
71
30
24
61
153
302
903
1,026
1,109
5,294
4,734
4,295
3,714
3,433
3,004
2,927
2,960
Working Capital
1
- -
- -
- -
- -
- -
- -
- -
- -
20
23
20
15
5
8
5
5
LT Debt
149
118
118
167
206
365
759
1,012
1,214
2,876
2,670
2,643
2,526
2,796
2,897
3,236
3,253
Total Equity
- -
- -
- -
- -
- -
- -
-2.03
- -
- -
- -
- -
- -
- -
2.34
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
90.16
- -
- -
- -
- -
- -
- -
-397.34
- -
- -
270.87
Return on Capital (%)
6.57
-53.66
-12.59
-16.32
44.95
-233.52
90.22
-173.17
- -
- -
- -
- -
- -
- -
65.76
96.63
182.59
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
2
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
6
5
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
66
66
66
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
3,162
3,079
3,061
Cash, Cash Equivalents & STI
3,050
2,998
2,982
Accounts Receivable, Net
45
10
22
Inventories
23
22
18
Total Current Liabilities
367
153
100
Payables & Accruals
101
34
97
ST Debt
2
2
2
Deferred Revenue
230
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
31.15%
4.11%
11.7%
Free Cash Flow
-275.46%
-10.97%
-32.53%
Net Income, GAAP
-133.45%
23.2%
333.15%
Sales/Revenue/Turnover
77.15%
53.96%
303.5%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
62
78
60
75
276
2025
75
65
71
901
1,112
2026
6
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.37
- -
- -
- -
1.12
2025
-2.33
- -
- -
- -
4.87
2026
0.22
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Shanghai Junshi Biosciences Co., Ltd. (688180.SS)
Enochian Biosciences, Inc. (ENOB)
Valerio Therapeutics S.A. (ALVIO.PA)
I-Tech AB (ITECH.ST)
Valneva SE (VLA.PA)
Voronoi, Inc. (310210.KQ)
Business
Galapagos NV (GLPG.BR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of innovative cell therapies and small molecule medicines addressing high unmet medical needs in oncology, immunology and other areas. The company offers a pipeline of cell therapy candidates including GLPG5101, a CD19-directed CAR T-cell therapy in Phase 2 for relapsed/refractory mantle cell lymphoma and non-Hodgkin lymphoma; GLPG5201 in Phase 1/2 for solid tumors; and GLPG5301 in Phase 1/2 for hematological malignancies, manufactured via a proprietary decentralized platform enabling fresh, stem-like early memory T-cells with a median vein-to-vein time of seven days; alongside small molecule assets such as the TYK2 inhibitor GLPG3667 in Phase 2 for systemic lupus erythematosus and dermatomyositis, which the company seeks partners for. Previously developed products include filgotinib (Jyseleca), a JAK1 inhibitor commercialized by partners for ulcerative colitis and rheumatoid arthritis in select markets. Galapagos operates in Europe, the United States and Asia, with additional sites in Leiden, Romainville, Basel, Milan, Madrid, Boston and Zagreb. Founded in 1999 and headquartered in Mechelen, Belgium, the company leverages proprietary platforms such as its high-yielding cell therapy discovery engine and xCellit workflow software for scalable, automated manufacturing without cryopreservation. Target markets encompass patients with hematological malignancies, solid tumors and autoimmune diseases, served through clinical trials, strategic partnerships and potential commercialization. In recent major developments, Galapagos announced on January 8, 2025, its intention to separate into two publicly traded entities by mid-2025: retaining cell therapy operations while spinning off SpinCo with €2.45 billion in capital, supported by Gilead Sciences, to pursue acquisitions in oncology, immunology and virology. However, on October 21, 2025, the company declared plans to wind down its cell therapy business amid financial pressures, including a €461.3 million net loss for the first nine months of 2025, shifting focus to value-accretive small molecule and biologics transactions leveraging its Gilead partnership. Key prior changes include the 2024 divestment of Jyseleca to Alfasigma SpA for €170 million; 2022 acquisitions of CellPoint and Abound Bio to bolster cell therapy capabilities; and manufacturing partnerships with NecstGen and CELLforCURE by SEQENS in 2025 for CAR T-cell production. GLPG5101 received FDA RMAT designation in 2025 for relapsed/refractory mantle cell lymphoma, highlighting pipeline progress prior to the strategic pivot.